The 12-week trial is with one of these new-generation SERMs, bazedoxifene. It uses the positive effects of estrogen, such as improving emotional symptoms, memory, information processing, concentration, and bone density, without affecting other parts of the body, such as the breast and ovaries, or feminising effects.